This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

9 Health Care Stocks With 100% Buy Ratings

3. OncoGenex Pharmaceuticals (OGXI - Get Report) is a biopharmaceutical company engaged in the development and commercialization of cancer therapies. The products focus on mechanisms of treatment resistance in cancer patients by blocking the production of specific proteins, which promote the survival of tumor cells and proliferate in response to a variety of cancer therapies. The company will report its first quarter 2011 results on May 9.

Net loss for the first quarter of 2011 is forecast at $4.8 million on sales of $2.6 million, compared to a net loss of $3 million on $4.7 million sales recorded during 2010 first quarter, according to analysts polled by Bloomberg. Loss per share is pegged at 52 cents, up from 48 cents per share reported during the comparable quarter last year.

The company recently announced that the European Patent Office (EPO) has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers." Scott Cormack, president and CEO of OncoGenex, said, "The issuance of this patent confirms our position as the leader in Hsp27 antisense therapeutics and provides us with a broad patent that applies well beyond particular cancers or particular compositions."

All the six analysts covering the stock rate a buy on it. According to analysts polled by Bloomberg, the stock has 137% upside over the next 12 months with a consensus target price of $37.
7 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
PATH $0.00 0.00%
ALIM $3.01 -5.05%
EBS $32.66 -2.71%
HSTM $24.29 0.21%
ICUI $110.36 -0.84%


Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs